Igor Puzanov

Director, Early Phase Clinical Trials

Roswell Park Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2025

Year:

2025

PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions. PATIENTS AND METHODS We conducted a multicenter observational trial (ClinicalTrials.gov identifier: NCT04056247 ) of patients undergoing PD-1/PD-L1 inhibitor–based therapy (n = 540) and an additional patient cohort receiving chemotherapy (n = 85) who consented to pretreatment plasma and clinical data collection. Plasma proteome profiling was performed using SomaScan Assay v4.1. RESULTS Our test demonstrates a strong association between model output and clinical benefit (CB) from PD-1/PD-L1 inhibitor–based treatments, evidenced by high concordance between predicted and observed CB ( R 2 = 0.98, P < .001). The test categorizes patients as either PROphet-positive or PROphet-negative and further stratifies patient outcomes beyond PD-L1 expression levels. The test successfully differentiates between PROphet-negative patients exhibiting high tumor PD-L1 levels (≥50%) who have enhanced overall survival when treated with a combination of immunotherapy and chemotherapy compared with immunotherapy alone (hazard ratio [HR], 0.23 [95% CI, 0.1 to 0.51], P = .0003). By contrast, PROphet-positive patients show comparable outcomes when treated with immunotherapy alone or in combination with chemotherapy (HR, 0.78 [95% CI, 0.42 to 1.44], P = .424). CONCLUSION Plasma proteome–based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor–based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (20)

Chen Hu

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

David Carbone

Ohio State University Medical Center

UNITED STATES
View details

Theodore Logan

Associate Professor Clinical Medicine

Indiana University School of Medicine

UNITED STATES
View details

Lei Deng

Assistant Professor

Fred Hutch Cancer Center

UNITED STATES
View details

george weiner

University of Iowa Healthcare

UNITED STATES
View details

Adam Dicker

Professor & Chair

Thomas Jefferson University

UNITED STATES
View details

Andrea Kasinski

Assistant Professor

Purdue University

UNITED STATES
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Allison Betof Warner

Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy

Stanford University

UNITED STATES
View details

Mohammed Milhem

Oncology Section Chief

University of Iowa Healthcare

UNITED STATES
View details

Aakrosh Ratan

Assistant Professor

University of Virginia

UNITED STATES
View details

Amod Sarnaik

Senior Member / Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Changchuan Jiang

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Xiaozhuo Liu

Research Associate

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jose Conejo-Garcia

Duke Science and Technology Scholar

Duke Medicine

UNITED STATES
View details

Shipra Gandhi

Emory University

UNITED STATES
View details

James L. Chen

Ohio State University

UNITED STATES
View details

David R. Gandara

Co-Director, Center for Experimental Therapeutics in Cancer

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Susanne Arnold

University of Kentucky

UNITED STATES
View details

Jason Chesney

University of Louisville

UNITED STATES
View details